Prothena Corporation plc - Ordinary Shares (PRTA) News

Prothena Corporation plc - Ordinary Shares (PRTA): $9.20

0.06 (-0.65%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add PRTA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#64 of 306

in industry

Filter PRTA News Items

PRTA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PRTA News Highlights

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

Latest PRTA News From Around the Web

Below are the latest news stories about PROTHENA CORP PUBLIC LTD CO that investors may wish to consider to help them evaluate PRTA as an investment opportunity.

Prothena Announces Board of Directors Update

DUBLIN, December 30, 2024--Prothena announced that Oleg Nodelman will step down from Prothena’s Board of Directors to create time to focus on existing and new endeavors.

Yahoo | December 30, 2024

We're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Yahoo | December 25, 2024

Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease

Prothena stock catapulted Thursday after the company's Roche-partnered Parkinson's treatment showed promise in a midstage study.

Yahoo | December 19, 2024

Prothena’s Parkinson’s study fails primary endpoint despite some success

Whilst Prothena has said that it is still examining the late-stage treatment, the company confirmed it failed to meet its primary endpoint of slowing disease motor progression.

Yahoo | December 19, 2024

Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease

DUBLIN, December 19, 2024--Prothena today announced results from PADOVA study conducted by partner Roche investigating prasinezumab in early-stage Parkinson’s disease.

Yahoo | December 19, 2024

Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 12, 2024

Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe

The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease.

Yahoo | November 15, 2024

Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus

PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter.

Yahoo | November 13, 2024

Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of 6.78% and 53.81%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 12, 2024

Prothena: Q3 Earnings Snapshot

DUBLIN (AP) — Prothena Corp. PRTA) on Tuesday reported a loss of $59 million in its third quarter. The Dublin-based company said it had a loss of $1.10 per share.

Yahoo | November 12, 2024


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!